Notably, VEGF inhibitors are showing benefits in clinical trials in combination with immunomodulatory agents (Hodi et al., 2014) (NCT02210117, NCT02348008, NCT01633970), albeit not in GBM. Here, VEGFA is linked to glioblastoma.